These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1240 related items for PubMed ID: 27685789

  • 1. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [Abstract] [Full Text] [Related]

  • 2. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.
    Endocrinology; 2013 Mar 10; 154(3):1247-59. PubMed ID: 23384836
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ, Cho BJ, Lee DJ, Hwang YH, Chun SH, Kim HH, Kim IA.
    BMC Cancer; 2014 Jan 13; 14():17. PubMed ID: 24418474
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
    Chen PH, Cheng CH, Shih CM, Ho KH, Lin CW, Lee CC, Liu AJ, Chang CK, Chen KC.
    PLoS One; 2016 Jan 13; 11(11):e0167096. PubMed ID: 27893811
    [Abstract] [Full Text] [Related]

  • 11. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M, Diesler K, Majhen D, Steigerwald C, Berte N, Freund H, Stojanović N, Kaina B, Osmak M, Ambriović-Ristov A, Tomicic MT.
    Oncotarget; 2017 Apr 25; 8(17):27754-27771. PubMed ID: 27487141
    [Abstract] [Full Text] [Related]

  • 12. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 13. Targeting hyperactivated DNA-PKcs by KU0060648 inhibits glioma progression and enhances temozolomide therapy via suppression of AKT signaling.
    Lan T, Zhao Z, Qu Y, Zhang M, Wang H, Zhang Z, Zhou W, Fan X, Yu C, Zhan Q, Song Y.
    Oncotarget; 2016 Aug 23; 7(34):55555-55571. PubMed ID: 27487130
    [Abstract] [Full Text] [Related]

  • 14. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z, Zhao G, Xie G, Zhao L, Chen Y, Yu H, Zhang Z, Li C, Li Y.
    Oncotarget; 2015 Oct 20; 6(32):32930-43. PubMed ID: 26431379
    [Abstract] [Full Text] [Related]

  • 15. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
    Fu J, Zhu SH, Xu HB, Xu YQ, Wang X, Wang J, Kong PS.
    J Ethnopharmacol; 2020 Oct 28; 261():113071. PubMed ID: 32603676
    [Abstract] [Full Text] [Related]

  • 16. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
    Kong S, Cao Y, Li X, Li Z, Xin Y, Meng Y.
    J Cell Mol Med; 2020 Apr 28; 24(8):4677-4686. PubMed ID: 32181582
    [Abstract] [Full Text] [Related]

  • 17. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K, Katoh T, Shimodaira H, Oda A, Takahashi O, Ishioka C.
    Cancer Sci; 2012 Nov 28; 103(11):1994-2001. PubMed ID: 22924958
    [Abstract] [Full Text] [Related]

  • 18. Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
    Grogan PT, Sarkaria JN, Timmermann BN, Cohen MS.
    Invest New Drugs; 2014 Aug 28; 32(4):604-17. PubMed ID: 24718901
    [Abstract] [Full Text] [Related]

  • 19. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
    Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC.
    Mol Cancer Ther; 2012 Nov 28; 11(11):2462-72. PubMed ID: 22933703
    [Abstract] [Full Text] [Related]

  • 20. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q, Liu J, Liu T, Zhang Q.
    Neuroscience; 2017 Mar 27; 346():298-308. PubMed ID: 28147244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.